Anti-inflammatory phytochemicals for chemoprevention of colon cancer

Current Cancer Drug Targets

Volumn 13, Issue 5, 2013, Pages 542-557

  Madka, Venkateshwar ^a   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemoprevention; Colon cancer; Inflammation; Natural compounds; Phytochemicals

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; ASTAXANTHIN; BOSWELLIC ACID; CINEOLE; CURCUMIN; CYCLOOXYGENASE 2; CYTOKINE; DIOSGENIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LICOFELONE; LINAZOLAST; LUPEOL; N [3 (AMINOMETHYL) BENZYL] ACETAMIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLEANOLIC ACID; PIPERINE; PIRINIXIC ACID; PLANT MEDICINAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YS 121;

ADENOCARCINOMA; ANGIOGENESIS; CANCER GROWTH; CANCER RISK; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHROMOSOMAL INSTABILITY; COLON CANCER; DISEASE ASSOCIATION; DNA DAMAGE; DNA FRAGMENTATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFLAMMATION; LIPID PEROXIDATION; METASTASIS; NEPHROTOXICITY; NONHUMAN; REVIEW; SKIN CARCINOGENESIS; TUMOR GROWTH; ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; HUMANS; INFLAMMATION; PHYTOCHEMICALS; PHYTOTHERAPY;

EID: 84886675158     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990036     Document Type: Review

References (247)

1. American Cancer Society. Cancer Facts & Figures 2013, Atlanta, Ga: American Cancer Society.
2. Haas, P.; Machado, M. J.; Anton, A. A.; Silva, A. S.; De Francisco, A. Effectiveness of whole grain consumption in the prevention of colorectal cancer: Meta-analysis of cohort studies. Int. J. Food Sci. Nutr. 2009, 21, 1-13.
3. Tantamango, Y. M.; Knutsen, S. F.; Beeson, W. L.; Fraser, G.; Sabate, J. Foods and food groups associated with the incidence of colorectal polyps: the Adventist Health Study. Nutr. Cancer. 2011, 63 (4), 565-572.
4. Peek, Jr. R. M.; Crabtree, J. E. Helicobacter infection and gastric neoplasia. J. Pathol. 2006, 208 (2), 233-248.
5. Martey, C. A.; Pollock, S. J.; Turner, C. K.; O'Reilly, K. M.; Baglole, C. J.; Phipps, R. P.; Sime, P. J. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287 (5), L981-L991.
6. Garcea, G.; Dennison, A. R.; Steward, W. P.; Berry, D. P. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 2005, 5 (6), 514-529.
7. Di Bisceglie, A. M. Hepatitis C and hepatocellular carcinoma. Hepatology 1997, 26 (3), 34S-38S.
8. Castle, P. E.; Hillier, S. L.; Rabe, L. K.; Hildesheim, A.; Herrero, R.; Bratti, M. C.; Sherman, M. E.; Burk, R. D.; Rodriguez, A. C.; Alfaro, M.; Hutchinson, M. L.; Morales, J.; Schiffman, M. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol. Biomarkers Prev. 2001, 10 (10), 1021-1027.
9. Offersen, B. V.; Knap, M. M.; Marcussen, N.; Horsman, M. R.; Hamilton-Dutoit, S.; Overgaard, J. Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis. Br. J. Cancer 2002, 87 (12), 1422-1430.
10. Stewart, B.W.; Kleihues, P. World Cancer Report, I.A.R.C. Publication 2003.
11. Kuper, H.; Adami, H. O.; Trichopoulos, D. Infections as a major preventable cause of human cancer, J. Intern. Med. 2000, 248, 171-183.
12. Markosyan, N.; Chen, E. P.; Ndong, V. N.; Yao, Y.; Sterner, C. J.; Chodosh, L. A.; Lawson, J. A.; Fitzgerald, G. A.; Smyth, E. M. Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis 2011, 32 (10), 1441-1449.
13. Rundhaug, J. E.; Fischer, S. M. Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. Photochem. Photobiol. 2008, 84 (2), 322-329.
14. Howe, L. R.; Chang, S. H.; Tolle, K. C.; Dillon, R.; Young, L. J.; Cardiff, R. D.; Newman, R. A.; Yang, P.; Thaler, H. T.; Muller, W. J.; Hudis, C.; Brown, A. M.; Hla, T.; Subbaramaiah, K.; Dannenberg, A. J. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 2005, 65 (21), 10113-10119.
15. Oshima, M.; Dinchuk, J. E.; Kargman, S. L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J. M.; Evans, J. F.; Taketo, M. M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87, 803-809.
16. Seril, D. N.; Liao, J.; Yang, G. Y. Colorectal carcinoma development in inducible nitric oxide synthase-deficient mice with dextran sulfate sodium-induced ulcerative colitis. Mol. Carcinog. 2007, 46 (5), 341-353.
17. Edelblum, K. L.; Goettel, J. A.; Koyama, T.; McElroy, S. J.; Yan, F.; Polk, D. B. TNFR1 promotes tumor necrosis factor-mediated mouse colon epithelial cell survival through RAF activation of NF-kappaB. J. Biol. Chem. 2008, 283 (43), 29485-29494.
18. Popivanova, B. K.; Kitamura, K.; Wu, Y.; Kondo, T.; Kagaya, T.; Kaneko, S.; Oshima, M.; Fujii, C.; Mukaida, N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 2008, 118 (2), 560-570.
19. Moore, B. B.; Arenberg, D. A.; Stoy, K.; Morgan, T.; Addison, C. L.; Morris, S. B.; Glass, M.; Wilke, C.; Xue, Y. Y.; Sitterding, S.; Kunkel, S. L.; Burdick, M. D.; Strieter, R. M. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am. J. Pathol. 1999, 154, 1503-1512.
20. Voronov, E.; Shouval, D. S.; Krelin, Y.; Cagnano, E.; Benharroch, D.; Iwakura, Y.; Dinarello, C. A.; Apte, R. N. IL-1 is required for tumor invasiveness and angiogenesis. PNAS. 2003, 100, 2645-2650.
21. Cahlin, C.; Korner, A.; Axelsson, H.; Wang, W.; Lundholm, K.; Svanberg, E. Cancer Res. 2000, 60, 5488-5493.
22. Huang, Y. J; Zhang, B.B; Ma, N; Murata, M; Tang, A. Z; Huang, G. W. Nitrative and oxidative DNA damage as potential survival biomarkers for nasopharyngeal carcinoma. Med. Oncol. 2011 28 (1), 377-384.
23. Jaiswal, M.; LaRusso, N. F.; Shapiro, R. A.; Billiar, T. R.; Gores, G. J. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001, 120 (1), 190-199.
24. Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature 2002, 420 (6917), 860-867.
25. Hoki, Y, Hiraku, Y.; Ma, N.; Murata, M.; Matsumine, A.; Nagahama, M.; Shintani, K.; Uchida, A.; Kawanishi, S. iNOS-dependent DNA damage in patients with malignant fibrous histiocytoma in relation to prognosis. Cancer Sci. 2007, 98, 163-168.
26. Hussain, S. P.; Amstad, P.; Raja, K.; Ambs, S.; Nagashima, M.; Bennett, W. P.; Shields, P. G.; Ham, A. J.; Swenberg, J. A.; Marrogi, A. J.; Harris, C. C. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000, 60 (13), 3333-3337.
27. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 2001, 357 (9255), 539-545.
28. Martel-Pelletier, J.; Pelletier, J. P.; Fahmi, H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum. 2003, 33, 155-167.
29. Zhang, L.; Bertucci, A. M.; Smith, K. A.; Xu, L.; Datta, S. K. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Arthritis Rheum. 2007, 56, 4132-4141.
30. Beyan, H.; Goodier, M. R.; Nawroly, N. S.; Hawa, M. I.; Bustin, S. A.; Ogunkolade, W. B.; Londei, M.; Yousaf, N.; Leslie, R. D. Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes. Diabetes 2006, 55, 3439-3445.
31. Muller-Decker, K.; Neufang, G.; Berger, I.; Neumann, M.; Marks, F.; Furstenberger, G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. PNAS. 2002, 99 (19), 12483-12488.
32. Oshima, H.; Oshima, M.; Inaba, K.; Taketo, M. M. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004, 23 (7), 1669-1678.
33. Tiano, H. F.; Loftin, C. D.; Akunda, J.; Lee, C. A.; Spalding, J.; Sessoms, A.; Dunson, D. B.; Rogan, E. G.; Morham, S. G.; Smart, R. C.; Langenbach, R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 2002, 62 (12), 3395-3401.
34. Lucci, A.; Krishnamurthy, S.; Singh, B.; Bedrosian, I.; Meric-Bernstam, F.; Reuben, J.; Broglio, K.; Mosalpuria, K.; Lodhi, A.; Vincent, L.; Cristofanilli, M. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res. Treat. 2009, 117 (1), 61-68.
35. Zhan, P; Qian, Q; Yu, L. K. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J. Thorac. Dis. 2013 5 (1), 40-47.
36. Peng, L; Zhou, Y; Wang, Y; Mou, H; Zhao, Q. Prognostic Significance of COX-2 Immunohistochemical Expression in Colorectal Cancer: A Meta-Analysis of the Literature. PLoS One. 2013, 8 (3), e58891.
37. Half, E.; Tang, X. M.; Gwyn, K.; Sahin, A.; Wathen, K.; Sinicrope, F. A. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002, 62 (6), 1676-1681.
38. Chan, G.; Boyle, J. O.; Yang, E. K.; Zhang, F.; Sacks, P. G.; Shah, J. P.; Edelstein, D.; Soslow, R. A.; Koki, A. T.; Woerner, B. M.; Masferrer, J. L.; Dannenberg, A. J. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999, 59 (5), 991-994.
39. Sales, K. J.; Katz, A. A.; Howard, B.; Soeters, R. P.; Millar, R. P.; Jabbour, H. N. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res. 2002, 62 (2), 424-432.
40. Klimp, A. H.; Hollema, H.; Kempinga, C.; van der Zee, A. G.; de Vries, E. G.; Daemen, T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res. 2001, 61 (19), 7305-7309.
41. Subbarayan, V.; Sabichi, A. L.; Llansa, N.; Lippman, S. M.; Menter, D. G. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res. 2001, 61 (6), 2720-2726.
42. Zimmermann, K. C.; Sarbia, M.; Weber, A. A.; Borchard, F.; Gabbert, H. E.; Schror, K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999, 59 (1), 198-204.
43. Tucker, O. N.; Dannenberg, A. J.; Yang, E. K.; Zhang, F.; Teng, L.; Daly, J. M.; Soslow, R. A.; Masferrer, J. L.; Woerner, B. M.; Koki, A. T.; Fahey, T. J. 3rd. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999, 59 (5), 987-990.
44. Mohammed, S. I.; Knapp, D. W.; Bostwick, D. G.; Foster, R. S.; Khan, K. N.; Masferrer, J. L.; Woerner, B. M.; Snyder, P. W.; Koki, A. T. Expression of cyclooxygenase-2 (COX-2) inhuman invasive transitional cell carcinoma(TCC) of the urinary bladder. Cancer Res. 1999, 59 (22), 5647-5650.
45. Brown, J. R.; DuBois, R. N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 2005, 23, 2840-2855.
46. Aparicio Gallego, G.; Diaz Prado, S.; Jimenez Fonseca, P.; Garcia Campelo, R.; Cassinello Espinosa, J.; Anton Aparicio, L. M. Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer. Clin. Transl. Oncol. 2007, 9, 694-702.
47. Zhao, X.; Goswami, M.; Pokhriyal, N.; Ma, H.; Du, H.; Yao, J.; Victor, T. A.; Polyak, K.; Sturgis, C. D.; Band, H.; Band, V. Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res. 2008, 68, 467-475.
48. Eberhart, C. E.; Coffey, R. J.; Radhika, A.; Giardiello, F. M.; Ferrenbach, S.; DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterol. 1994, 107, 1183-1188.
49. DuBois, R. N.; Radhika, A.; Reddy, B. S.; Entingh, A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterol. 1996, 110, 1259-1262.
50. Tsujii, M.; DuBois, R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83, 493-501.
51. Marnett, L.J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 1992, 52, 5575-5589.
52. Smith, W. L.; DeWitt, D. L; Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. Ann. Rev. Biochem. 2000, 69, 145-182.
53. Sheng, H.; Shao, J.; Kirkland, S. C.; Isakson, P.; Coffey, R. J.; Morrow, J.; Beauchamp, R. D.; DuBois, R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclo-oxygenase-2. J. Clin. Invest. 1997, 99, 2254-2259.
54. Elder, D. J.; Halton, D. E.; Hague, A.; Paraskeva, C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 1997, 3, 1679-1683.
55. Liu, W.; Reinmuth, N.; Stoeltzing, O.; Parih, A. A.; Tellez, C.; Williams, S.; Jung, Y. D.; Fan, F.; Takeda, A.; Akagi, M.; Bar-Eli, M.; Gallick, G. E.; Ellis, L. M. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res. 2003, 63 (13), 3632-3636.
56. Tang, X.; Sun, Y. J.; Half, E.; Kuo, M. T.; Sinicrope, F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002, 62 (17), 4903-4908.
57. Sun, Y.; Tang, X. M.; Half, E.; Kuo, M. T.; Sinicrope, F. A. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002, 62 (21), 6323-6328.
58. Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93 (5), 705-716.
59. Souza, R. F.; Shewmake, K.; Beer, D. G.; Cryer, B.; Spechler, S. J. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000, 60 (20), 5767-5772.
60. Werz, O.; Steinhilber, D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol. Ther. 2006, 112, 701-718.
61. Furstenberger, G.; Krieg, P.; Muller-Decker, K.; Habenicht, A. J. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 2006, 119, 2247-2254.
62. Kelavkar, U. P.; Nixon, J. B.; Cohen, C.; Dillehay, D.; Eling, T. E.; Badr, K. F. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 2001, 22(11), 1765-1773.
63. Boado, R. J.; Pardridge, W. M.; Vinters, H. V.; Black, K. L. Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. PNAS. 1992, 89(19), 9044-9048.
64. Hennig, R.; Ding, X. Z.; Tong, W.; Schneider, M. B.; Standop, J.; Friess, H.; Büchler, M. W.; Pour, P. M.; Adrian, T. E. 5-Lipoxygenase and leukotrieneB(4) receptor are expressed in humanpancreatic cancersbut not in pancreatic ducts in normal tissue. Am J Pathol. 2002, 161, 421-428.
65. McCarty, M. F. Targetingmultiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr. Cancer Ther. 2004, 3, 349-380.
66. Ghosh, J. Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem. Biophys. Res. Commun. 2004, 315, 624-635.
67. Steinbrink, S. D.; Pergola, C.; Bühring, U.; George, S.; Metzner, J.; Fischer, A. S.; Häfner, A. K.; Wisniewska, J. M.; Geisslinger, G.; Werz, O.; Steinhilber, D.; Maier, T. J. Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations. Cell Mol. Life Sci. 2009, 67, 797-806.
68. Melstrom, L. G.; Bentrem, D. J.; Salabat, M. R.; Kennedy, T. J.; Ding, X. Z.; Strouch, M.; Rao, S. M.; Witt, R. C.; Ternent, C. A.; Talamonti, M. S.; Bell, R. H.; Adrian, T. A.Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors In vitro and in a murine model. Clin. Cancer Res. 2008, 14, 6525-6530.
69. Ye, Y. N.; Wu, W. K.; Shin, V. Y.; Bruce, I. C.; Wong, B. C.; Cho, C. H. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005, 26 (4), 827-834.
70. Mohammed, A.; Janakiram, N. B.; Li, Q.; Choi, C. I.; Zhang, Y.; Steele, V. E.; Rao, C. V. Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev. Res. 2011, 4 (12), 2015-2026.
71. Sharma, S.; Lee, J.; Zhou, J.; Steele, V. E. Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration. Cancer Prev Res (Phila). 2011, 4 (8), 1233-1242.
72. Rioux, N.; Castonguay, A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 1998, 19 (8), 1393-1400.
73. Jiang, H.; Yamamoto, S.; Kato, R. Inhibition of two-stage skin carcinogenesis as well as complete skin carcinogenesis by oral administration of TMK688, a potent lipoxygenase inhibitor. Carcinogenesis 1994, 15 (5), 807-812.
74. Werz, O.; Greiner, C; Koeberle, A.; Hoernig, C; George, S.; Popescu, L.; Syha, I.; Schubert-Zsilavecz, M.; Steinhilber, D. Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J. Med. Chem. 2008, 51, 5449-5453.
75. Cheon, E. C; Khazaie, K.; Khan, M. W.; Strouch, M. J.; Krantz, S. B.; Phillips, J.; Blatner, N. R.; Hix, L. M.; Zhang, M.; Dennis, K. L.; Salabat, M. R.; Heiferman, M.; Grippo, P. J.; Munshi, H. G.; Gounaris, E.; Bentrem, D. J. Mast cell 5-lipoxygenase activity promotes intestinal polyposis in Apc8468 mice. Cancer Res. 2011, 71 (5), 1627-1636.
76. Cheon, E. C; Strouch, M. J.; Krantz, S. B.; Heiferman, M. J.; Bentrem, D. J. Genetic deletion of 5-lipoxygenase increases tumor-infiltrating macrophages in Apc(8468) mice. J. Gastrointest. Surg. 2012, 16 (2), 389-393.
77. Bogdan, C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2 (10), 907-916.
78. Nathan, C; Xie, Q. W. Nitric oxide synthases: roles, tolls, and controls. Cell 1994, 78, 915-918.
79. Forstermann, U.; Kleinert, H. Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch. Pharmacol. 1995, 352, 351-364.
80. Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992, 6 (12), 3051-3064.
81. Geller, D. A.; Billiar, T. R. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev. 1998, 17 (1), 7-23.
82. Lirk, P.; Hoffmann, G.; Rieder, J.; Inducible nitric oxide synthase time for reappraisal. Curr. Drug Targets Inflamm. Allergy 2002, 1 (1), 89-108.
83. Chen, T.; Stoner, G. D. Inducible nitric oxide synthase expression in N-nitrosomethylbenzylamine (NMBA)-induced rat esophageal tumorigenesis. Mol. Carcinog. 2004, 40, 232-240.
84. Jaiswal, M.; LaRusso, N. F.; Gores, G. J. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 281, G626-G634.
85. Thomsen, L. L.; Lawton, F. G.; Knowles, R. G.; Beesley, J. E.; Riveros-Moreno, V.; Moncada, S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 1994, 54, 1352-1354.
86. Thomsen, L. L.; Miles, D. W.; Happerfield, L.; Bobrow, L. G.; Knowles, R. G.; Moncada, S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 1995, 72, 41-44.
87. Cobbs, C. S.; Brenmen, J. E.; Aldape, K. D.; Bredt, D. S.; Israel, M. A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995, 55, 727-730.
88. Wilson, K. T.; Fu, S.; Ramanujam, K. S.; Meltzer, S. J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 1998, 58, 2929-2934.
89. Rieder, G.; Hofmann, J. A.; Hatz, R. A.; Stolte, M.; Enders, G. A. Up-regulation of inducible nitric oxide synthase in Helicobacter pylori-associated gastritis may represent an increased risk factor to develop gastric carcinoma of the intestinal type. Int. J. Med. Microbiol. 2003, 293, 403-412.
90. Aaltoma, S. H.; Lipponen, P. K.; Kosma, V. M. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res. 2001, 21, 3101-3106.
91. Ohshima, H.; Bartsch, H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res. 1994, 305, 253-264.
92. Ambs, S.; Merriam, W. G.; Bennett, W. P.; Felley-Bosco, E.; Ogunfusika, M. O.; Oser, S. M.; Klein, S.; Shields, P. G.; Billiar, T. R.; Harris, C. C. Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression. Cancer Res. 1998, 58, 334-341.
93. Rao, C. V.; Kawamori, T.; Hamid, R.; Simi, B.; Gambrell, B.; Reddy, B. S. Chemoprevention of colon cancer by iNOS specific and non-specific inhibitors: a safer colon cancer chemopreventive strategy. Proc. Am. Assoc. Cancer Res. 1998, 39, 197.
94. Takahashi, M.; Fukuda, K.; Ohata, T.; Sugimura, T.; Wakabayashi, K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res. 1997, 57, 1233-1237.
95. Kohno, H.; Suzuki, R.; Sugie, S.; Tanaka, T. b-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci. 2005, 96, 69-76.
96. Tanaka, T.; Kohno, H.; Suzuki, R.; Hata, K.; Sugie, S.; Niho, N.; Sakano, K.; Takahashi, M.; Wakabayashi, K. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in ApcMin/+ mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer 2006, 118, 25-34.
97. Tamir, S.; Burney, S.; Tannenbaum, S. DNA damage by nitric oxide. Chem. Res. Toxicol. 1996, 9, 821-827.
98. Jaiswal, M.; LaRusso, N. F.; Burgart, L.; Gores, G. Inflammatory cytokines induce DNA damage and inhibit DNA repair in colonic carcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000, 60, 184-189.
99. Fukumura, D.; Jain, R. Role of angiogenesis and microcirculation in tumors. Cancer Metastasis Rev. 1998, 17, 77-89.
100. Landino, L. M.; Crews, B. C.; Timmons, M. D.; Morrow, J. D.; Marnett, L. J. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. PNAS. 1996, 93, 15069-15074.
101. Kohno, H.; Suzuki, R.; Sugie, S.; Tanaka, T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005, 5, 46.
102. Kohno, H.; Takahashi, M.; Yasui, Y.; Suzuki, R.; Miyamoto, S.; Kamanaka, Y.; Naka, M.; Maruyama, T.; Wakabayashi, K.; Tanaka, T. A specific inducible nitric oxide synthase inhibitor, ONO-1714 attenuates inflammation-related large bowel carcinogenesis in male ApcMin/+ mice, Int. J. Cancer 2007, 121, 506-513.
103. Chun, K. S.; Cha, H. H.; Shin, J. W.; Na, H. K.; Park, K. K.; Chung, W. Y.; Surh, Y. J. Nitric oxide induces expression of cyclooxygenase-2 in mouse skin through activation of NFkB, Carcinogenesis 2004, 25, 445-454.
104. Rao, C. V.; Indranie, C.; Simi, B.; Manning, P. T.; Connor, J. R.; Reddy, B. S. Chemopreventive Properties of a Selective Inducible Nitric Oxide Synthase Inhibitor in Colon Carcinogenesis, Administered Alone or in Combination with Celecoxib, a Selective Cyclooxygenase-2 Inhibitor. Cancer Res. 2002, 62, 165-170.
105. Rao, C. V.; Kawamori, T.; Hamid, R.; Reddy, B. S. Chemo-prevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 2000, 21, 617-621.
106. Thomsen, L. L.; Scott, J. M.; Topley, P.; Knowles, R. G.; Keerie, A. J.; Frend, A. J. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res. 1997, 57 (15), 3300-3304.
107. Balkwill, F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002, 13 (2), 135-141.
108. Montesano, R.; Soulie, P.; Eble, J. A.; Carrozzino, F. Tumour necrosis factor alpha confers an invasive, transformed phenotype on mammary epithelial cells. J. Cell Sci. 2005, 118 (15), 3487-3500.
109. Kalthoff, H.; Roeder, C.; Gieseking, J.; Humburg, I.; Schmiegel, W. Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. PNAS. 1993, 90 (19), 8972-8976.
110. Giri, D. K.; Aggarwal, B. B. Constitutive activation of NFkappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role oftumor necrosis factor and reactive oxygen intermediates. J. Biol. Chem. 1998, 273 (22), 14008-14014.
111. Liu, R. Y.; Fan, C.; Mitchell, S.; Chen, Q.; Wu, J.; Zuckerman, K. S. The role of type I and type II tumor necrosis factor (TNF) receptors in the ability of TNF-alpha to transduce a proliferative signal in the human megakaryoblastic leukemic cell line Mo7e. Cancer Res. 1998, 58 (10), 2217-2223.
112. Schmiegel, W.; Roeder, C.; Schmielau, J.; Rodeck, U.; Kalthoff, H. Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. PNAS. 1993, 90 (3), 863-867.
113. Mizoguchi, E.; Mizoguchi, A.; Takedatsu, H.; Cario, E.; de Jong, Y. P.; Ooi, C. J.; Xavier, R. J.; Terhorst, C.; Podolsky, D. K.; Bhan, A. K. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterol. 2002, 122 (1), 134-144.
114. Szlosarek, P.; Charles, K. A.; Balkwill, F. R. Tumour necrosis factor-a as a tumour promoter. Eur. J. Cancer 2006, 42, 745-750.
115. Onizawa, M.; Nagaishi, T.; Kanai, T.; Nagano, K.; Oshima, S.; Nemoto, Y.; Yoshioka, A.; Totsuka, T.; Okamoto, R.; Nakamura, T.; Sakamoto, N.; Tsuchiya, K.; Aoki, K.; Ohya, K.; Yagita, H.; Watanabe, M. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296 (4), G850-G859.
116. Neta, R.; Sztein, M. B.; Oppenheim, J. J.; Gillis, S.; Douches, S. D. The in vivo effects of interleukin 1. I. Bone marrow cells are induced to cycle after administration of interleukin 1. J. Immunol. 1987, 139, 1861-1866.
117. Alexandroff, A. B.; Jackson, A. M.; Esuvaranathan, K.; Prescott, S.; James, K. Autocrine regulation of ICAM-1 expression on bladder cancer cell lines: evidence for the role of IL-1 alpha. Immunol. Lett. 1994, 40, 117-124.
118. Burger, R. A.; Grosen, E. A.; Ioli, G. R.; Van Eden, M. E.; Brightbill, H. D.; Gatanaga, M.; Disaia, P. J.; Granger, G. A.; Gatanaga, T. Host-tumor interaction in ovarian cancer. Spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro. Gynecol. Oncol. 1994, 55, 294-303.
119. Castelli, C; Sensi, M.; Lupetti, R.; Mortarini, R.; Panceri, P.; Anichini, A.; Parmiani, G. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. Cancer Res. 1994, 54, 4785-4790.
120. Tyler, D. S.; Francis, G. M.; Frederick, M.; Tran, A. H.; Ordonez, N. G.; Smith, J. L.; Eton, O.; Ross, M.; Grimm, E. A. Interleukin-1 production in tumor cells of human melanoma surgical specimens. J. Interferon Cytokine Res. 1995, 15, 331-340.
121. Von Schweinitz, D.; Hadam, M. R.; Welte, K.; Mildenberger, H.; Pietsch, T. Production of interleukin-1 beta and interleukin-6 in hepatoblastoma. Int. J. Cancer 1993, 53, 728-734.
122. Ishihara, K.; Hirano, T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002, 13, 357-368.
123. Moller, B.; Villiger, P. M. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin. Immunopathol. 2006, 27, 391-408.
124. Nishimoto, N.; Kishimoto, T. Inhibition of IL-6 for the treatment of inflammatory diseases.Curr. Opin. Pharmacol. 2004, 4, 386-391.
125. Bommert, K.; Bargou, R. C; Stuhmer, T. Signalling and survival pathways in multiple myeloma. Eur. J. Cancer 2006, 42, 1574-1580.
126. Cozen, W.; Gill, P. S.; Ingles, S. A.; Masood, R.; Martinez-Maza, O.; Cockburn, M. G.; Gauderman, W. J.; Pike, M. C; Bernstein, L.; Nathwani, B. N., Salam, M. T.; Danley, K. L.; Wang, W.; Gage, J.; Gundell-Miller, S.; Mack, T. M. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2004, 103, 3216-3221.
127. Osborne, J.; Moore, P. S.; Chang, Y. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum. Immunol. 1999, 60 (10), 921-927.
128. Naito, Y.; Takagi, T.; Uchiyama, K.; Kuroda, M.; Kokura, S.; Ichikawa, H.; Yanagisawa, R.; Inoue, K.; Takano, H.; Satoh, M.; Yoshida, N.; Okanoue, T.; Yoshikawa, T. Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice. Int. J. Mol. Med. 2004, 14 (2), 191-196.
129. Yamada, H. Y.; Yao, Y.; Wang, X.; Zhang, Y.; Huang, Y.; Dai, W.; Rao, C. V. Haploinsufficiency of SGO1 results in deregulated centrosome dynamics, enhanced chromosomal instability and colon tumorigenesis. Cell Cycle 2012, 11 (3), 479-488.
130. Benchetrit, F.; Ciree, A.; Vives, V.; Warnier, G.; Gey, A.; Sautès-Fridman, C; Fossiez, F.; Haicheur, N.; Fridman, W. H.; Tartour, E. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002, 99 (6), 2114-2121.
131. Niu, J.; Li, Z.; Peng, B.; Chiao, P. J. Identification of an autoregulatory feedback pathway involving interleukin-1 alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J. Biol. Chem. 2004, 279 (16), 16452-16456.
132. Jung, Y. J.; Isaacs, J. S.; Lee, S.; Trepel, J.; Neckers, L. IL-1betamediated up-regulation of HIF-1alpha via an NfkappaB/ COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003, 17 (14), 2115-2117.
133. Landi, S.; Moreno, V.; Gioia-Patricola, L.; Guino, E.; Navarro, M.; de Oca, J.; Capella, G.; Canzian, F. Bellvitge Colorectal Cancer Study Group. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFkB1, and peroxisome proliferatoractivated receptor gamma with colorectal cancer. Cancer Res. 2003, 63 (13), 3560-3566.
134. McCarron, S. L.; Edwards, S.; Evans, P. R.; Gibbs, R.; Dearnaley, D. P.; Dowe, A.; Southgate, C; Easton, D. F.; Eeles, R. A.; Howell, W. M. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002, 62 (12), 3369-3372.
135. Huang, S.; Mills, L.; Mian, B.; Tellez, C; McCarty, M.; Yang, X. D.; Gudas, J. M.; Bar-Eli, M. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 2002, 161 (1), 125-134.
136. Griffin, J. D. Leukemia stem cells and constitutive activation of NFkB. Blood 2001, 98, 2291.
137. Palayoor, S. T.; Youmell, M. Y.; Calderwood, S. K.; Coleman, C. N.; Price, B. D. Constitutive activation of IkB kinase a and NFkB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999, 18, 7389-7394.
138. Nakshatri, H.; Bhat-Nakshatri, P.; Martin, D. A.; Goulet, R. J. Jr.; Sledge, G. W. Jr. Constitutive activation of NFkB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 1997, 17, 3629-3639.
139. Farina, A. R.; Tacconelli, A.; Vacca, A.; Maroder, M.; Gulino, A.; Mackay, A. R. Transcriptional up-regulation of matrix metalloproteinase9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kB elements. Cell Growth Differ. 1999, 10, 353-367.
140. Bond, M.; Fabunmi, R. P.; Baker, A. H.; Newby, A. C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NFkB. FEBS Lett. 1998, 435, 29-34.
141. Novak, U.; Cocks, B. G.; Hamilton, J. A. A labile repressor acts through the NFKB-like binding sites of the human urokinase gene. Nucleic Acids Res. 1991, 19, 3389-3393.
142. Van de Stolpe, A.; Caldenhoven, E.; Stade, B. G.; Koenderman, L.; Raaijmakers, J. A.; Johnson, J. P.; van der Saag, P. T. 12-Otetradecanoylphorbol-13-acetate- and tumor necrosis factor a-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J. Biol. Chem. 1994, 269, 6185-6192.
143. Greten, F. R.; Eckmann, L.; Greten, T. F.; Park, J. M.; Li, Z. W.; Egan, L. J.; Kagnoff, M. F.; Karin, M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118, 285-296.
144. Pikarsky, E.; Porat, R. M.; Stein, I.; Abramovitch, R.; Amit, S.; Kasem, S.; Gutkovich-Pyest, E.; Urieli-Shoval, S.; Galun, E.; Ben-Neriah, Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431, 461-466.
145. Al-Halabi, R.; Bou Chedid, M.; Abou Merhi, R.; El-Hajj, H.; Zahr, H.; Schneider-Stock, R.; Bazarbachi, A.; Gali-Muhtasib, H. Gallotannin inhibits NFkB signaling and growth of human colon cancer xenografts. Cancer Biol Ther. 2011, 12(1), 59-68.
146. Nagendraprabhu, P.; Sudhandiran G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Invest New Drugs. 2011, 29 (2), 207-224.
147. Umesalma, S.; Sudhandiran G. Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-kappaB, iNOS, COX-2, TNF-alpha, and IL-6 in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Basic Clin. Pharmacol. Toxicol. 2010, 107 (2), 650-655.
148. Rao, C. V.; Rivenson, A.; Simi, B.; Reddy, B. S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995, 55 (2), 259-266.
149. Pradeep, C. R.; Kuttan, G. Piperine is a potent inhibitor of nuclear factor-kappaB (NF-kappaB), c-Fos, CREB, ATF-2 and proinflammatory cytokine gene expression in B16F-10 melanoma cells. Int. Immunopharmacol. 2004, 4, 1795-1803.
150. Raju, J.; Malisetty, V. S.; Patlolla, J. M. R.; Rao, C. V. Diosgenin, a steroid saponin of Trigonella foenum graecum (Fenugreek), inhibits azoxymethane-induced aberrant crypt foci formation in F344 rats and induces apoptosis in HT-29 human colon cancer cells. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 1392-1398.
151. Janakiram, N. B.; Indranie, C.; Malisetty, S. V.; Jagan, P.; Steele, V. E.; Rao, C. V. Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells. Pharm. Res. 2008, 25 (9), 2151-2157.
152. Srimal, R. C.; Khanna, N. M.; Dhawan, B. N. A preliminary report on anti inflammatory activity of curcumin. Int. J. Pharm. 1971, 3, 10-13.
153. Mukhopadhyay, A.; Basu, N.; Ghatak, N. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 1982, 12, 508-515.
154. Satoskar, R. R.; Shah, S. J.; Shenoy, S. G. Evaluation of anti-inflammatory property of curcumin in patients with postoperative inflammation. Int. J. Clin. Pharmacol. Ther. Toxicol. 1986, 24, 651-654.
155. Biswas, S. K.; McClure, D.; Jimenez, L. A.; Megson, I. L.; Rahman, I. Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: Mechanism of free radical scavenging activity. Antioxid. Redox. Signal. 2005, 7, 32-41.
156. Rao, C. V.; Simi, B.; Reddy, B. S. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 1993, 14 (11), 2219-2225.
157. Kawamori, T.; Lubet, R.; Steele, V. E.; Kelloff, G. J.; Kaskey, R. B.; Rao, C. V.; Reddy, B. S. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 1999, 59(3), 597-601.
158. Carroll, R. E.; Benya, R. V.; Turgeon, D. K.; Vareed, S.; Neuman, M.; Rodriguez, L.; Kakarala, M.; Carpenter, P. M.; McLaren, C.; Meyskens, F. L. Jr.; Brenner, D. E. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev. Res. 2011, 4 (3), 354-364.
159. Shpitz, B.; Giladi, N.; Sagiv, E.; Lev-Ari, S.; Liberman, E.; Kazanov, D.; Arber, N. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006, 74 (3-4), 140-144.
160. Xu, G.; Ren, G.; Xu, X.; Yuan, H.; Wang, Z.; Kang, L.; Yu, W.; Tian, K. Combination of curcumin and green tea catechins prevents dimethylhydrazine-induced colon carcinogenesis. Food Chem. Toxicol. 2010, 48 (1), 390-395.
161. Bajad, S.; Bedi, K.L.; Singla, A. K.; Johri, R. K. Piperine inhibits gastric emptying and gastro-intestinal tansit in rats and mice. Planta Med. 2001, 67, 176-179.
162. Khajuria, A.; Thusu, N.; Zutshi, U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: Influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine 2002, 9, 224-231.
163. Atal, C. K.; Dubey, R. K.; Singh, J. Biochemical basis of enhanced drug bioavailability of piperine: evidence that piperine is a potent inhibitor of drug metabolism. J. Pharmacol. Exp. Ther. 1985, 232, 258-262.
164. Bhardwaj, R. K.; Glaeser, H.; Becquemont, L.; Klotz, U.; Gupta, S. K.; Fromm, M. F. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 2002, 302 (2), 645-650.
165. Mittal, R.; Gupta, R. L. Invitro antioxidant activity of piperine. Exp. Clin. Pharmacol. 2000, 22, 271-274.
166. Pradeep, C. R.; Kuttan, G. Effect of piperine on the production of nitric oxide and TNF-a In vitro as well as in vivo. Immuno-pharmacol. Immunotoxicol. 1999, 25, 337-346.
167. Pradeep, C. R.; Kuttan, G. Effect of piperine on the inhibition of lung metastasis induced B16F-10 melanoma cells in mice. Clin. Exp. Metastasis 2002, 19, 703-708.
168. Selvendiran, K.; Thirunavukkarasu, C.; Singh, J. P.; Padmavathi, R.; Sakthisekaran, D. Chemopreventive effect of piperine on mitochondrial TCA cycle and phase-I and glutathione-metabolizing enzymes in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. Mol. Cell Biochem. 2005, 271 (1-2), 101-106.
169. Selvendiran, K.; Banu, S. M.; Sakthisekaran, D. Oral supplementation of piperine leads to altered phase II enzymes and reduced DNA damage and DNA-protein cross links in Benzo(a)pyrene induced experimental lung carcinogenesis. Mol. Cell Biochem. 2005, 268 (1-2), 141-147.
170. Bezerra, D. P.; Castro, F. O.; Alves, A. P.; Pessoa, C.; Moraes, M. O.; Silveira, E. R.; Lima, M. A.; Elmiro, F. J.; Costa-Lotufo, L. V. In vivo growth-inhibition of Sarcoma 180 by piplartine and piperine, two alkaloid amides from Piper. Braz. J. Med. Biol. Res. 2006, 39 (6), 801-807.
171. Nalini, N.; Manju, V.; Menon, V. P. Effect of spices on lipid metabolism in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. J. Med. Food 2006, 9, 237-245.
172. Selvendiran, K.; Sakthisekaran, D. Chemopreventive effect of piperine on modulating lipid peroxidation and membrane bound enzymes in benzo(alpha)pyrene induced lung carcinogenesis. Biomed. Pharmacother. 2004, 58, 264-267.
173. Duessel, S.; Heuertz, R. M.; Ezekiel, U. R. Growth inhibition of human colon cancer cells by plant compounds. Clin. Lab Sci. 2008, 21 (3), 151-157.
174. Liu, Y.; Yadev, V. R.; Aggarwal, B. B.; Nair, M. G. Inhibitory effects of black pepper (Piper nigrum) extracts and compounds on human tumor cell proliferation, cyclooxygenase enzymes, lipid peroxidation and nuclear transcription factor-kappa-B. Nat. Prod. Commun. 2010, 5 (8), 1253-1257.
175. Sehgal, A.; Kumar, M.; Jain, M.; Dhawan D. K. Combined effects of curcumin and piperine in ameliorating benzo(a)pyrene induced DNA damage. Food Chem. Toxicol. 2011, 49 (11), 3002-3006.
176. Gupta, A.; Gupta, R.; Lal, B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J. Assoc. Physicians India 2001, 49, 1057-1061.
177. Pandian, R. S.; Anuradha, C. V.; Viswanathan, P. Gastroprotective effect of fenugreek seeds (Trigonella foenum graecum) on experimental gastric ulcer in rats. J. Ethnopharmacol. 2002, 81 (3), 393-397.
178. Sauvaire, Y.; Ribes, G.; Baccou, J. C.; Loubatieères-Mariani, M. M. Implication of steroid saponins and sapogenins in the hypocholesterolemic effect of fenugreek. Lipids 1991, 26 (3), 191-197.
179. Chevallier, A. 2000, Encyclopedia of herbal medicine. New York (NY): Dorling Kindersley Publishing, Inc, 271.
180. Basch, E.; Ulbricht, C.; Kuo, G.; Szapary, P.; Smith, M. Therapeutic applications of fenugreek. Altern. Med. Rev. 2003, 8, 20-27.
181. Raju, J.; Gupta, D.; Rao, A. R.; Yadava, P. K.; Baquer, N. Z. Trigonella foenum graecum (fenugreek) seed powder improves glucose homeostasis in alloxan diabetic rat tissues by reversing the altered glycolytic, gluconeogenic and lipogenic enzymes. Mol. Cell Biochem. 2001, 224, 45-51.
182. Murakami, T.; Kishi, A.; Matsuda, H.; Yoshikawa, M. Medicinal foodstuffs. XVII. Fenugreek seed (3): structures of new furostanol-type steroid saponins, trigoneosides Xa, Xb, XIb, XIIa, XIIb, and XIIIa, from the seeds of Egyptian Trigonella foenum graecum L. Chem. Pharm. Bull (Tokyo), 2000, 48, 994-1000.
183. Yoshikawa, M.; Murakami, T.; Komatsu, H.; Murakami, N.; Yamahara, J.; Matsuda, H. Medicinal foodstuffs. IV. Fenugreek seed (1): structures of trigoneosides Ia, Ib, IIa, IIb, IIIa, and IIIb, new furostanol saponins from the seeds of Indian Trigonella foenum graecum L. Chem. Pharm. Bull (Tokyo) 1997, 45, 81-87.
184. Sur, P.; Das, M.; Gomes, A.; Vedasiromoni, J. R.; Sahu, N. P.; Banerjee, S.; Sharma, R. M.; Ganguly, D. K. Trigonella foenum graecum (fenugreek) seed extract as an antineoplastic agent. Phytother. Res. 2001, 15, 257-259.
185. Moalic, S.; Liagre, B.; Corbière, C.; Bianchi, A.; Dauça, M.; Bordji, K.; Beneytout, J. L. A plant steroid, diosgenin, induces apoptosis, cell cycle arrest and COX activity in osteosarcoma cells. FEBS Lett. 2001, 506(3), 225-230.
186. Li, F.; Fernandez, P. P.; Rajendran, P.; Hui, K. M.; Sethi, G. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Letters 2010, 292 (2), 197-207.
187. Lepage, C.; Léger, D.Y.; Bertrand, J.; Martin, F.; Beneytout, J.L.; Liagre B. Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Letters 2011, 301 (2), 193-202
188. Yamada, T.; Hoshino, M.; Hayakawa, T.; Ohhara, H.; Yamada, H.; Nakazawa, T.; Inagaki, T.; Iida, M.; Ogasawara, T.; Uchida, A.; Hasegawa, C.; Murasaki, G.; Miyaji, M.; Hirata, A.; Takeuchi, T. Dietary diosgenin attenuates subacute intestinal inflammation associated with indomethacin in rats. Am. J. Physiol. 1997, 273, G355-364.
189. Miyoshi, N.; Nagasawa, T.; Mabuchi, R.; Yasui, Y.; Wakabayashi, K.; Tanaka, T.; Ohshima, H. Chemoprevention of azoxymethane/ dextran sodium sulfate-induced mouse colon carcinogenesis by freeze-dried yam sanyaku and its constituent diosgenin. Cancer Prev. Res. (Phila). 2011, 4 (6), 924-934.
190. Ding, X. Z.; Adrian, T. E. Resveratrol inhibits proliferationand induces apoptosis in human pancreatic cancer cells. Pancreas 2002, 25, e71-e76.
191. Holian, O.; Wahid, S.; Atten, M. J.; Attar, B. M. Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282, G809-G816.
192. Zhou, H. B.; Yan, Y.; Sun, Y. N.; Zhu, J. R. Resveratrol induces apoptosis in human esophageal carcinoma cells. World J. Gastroenterol. 2003, 9, 408-411.
193. Hsieh, T. C.; Wu, J. M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res. 1999, 249, 109-115.
194. Niles, R. M.; McFarland, M.; Weimer, M. B.; Redkar, A.; Fu, Y. M.; Meadows, G. G. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett. 2003, 190, 157-163.
195. Kim, Y. A.; Lee, W. H.; Choi, T. H.; Rhee, S. H.; Park, K. Y.; Choi, Y. H. Involvement of p21WAF1/ CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int. J. Oncol. 2003, 23, 1143-1149.
196. Kozuki, Y.; Miura, Y.; Yagasaki, K. Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action. Cancer Lett. 2001, 167, 151-156.
197. Shih, A.; Davis, F. B.; Lin, H. Y.; Davis, P. J. Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. J. Clin. Endocrinol. Metab. 2002, 87, 1223-1232.
198. Bhat, K. P.; Pezzuto, J. M. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adeno-carcinoma (Ishikawa) cells. Cancer Res. 2001, 61, 6137-6144.
199. ElAttar, T. M.; Virji, A. S. Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anticancer Drugs 1999, 10, 187-193.
200. Opipari, A. W. Jr.; Tan, L.; Boitano, A. E.; Sorenson, D. R.; Aurora, A.; Liu, J. R.; Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res. 2004, 64, 696-703.
201. Liang, Y. C.; Tsai, S. H.; Chen, L.; Lin-Shiau, S. Y.; Lin, J. K. Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem. Pharmacol. 2003, 65, 1053-1060.
202. Subbaramaiah, K.; Chung, W. J.; Michaluart, P.; Telang, N.; Tanabe, T.; Inoue, H.; Jang, M.; Pezzuto, J. M.; Dannenberg, A. J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 1998, 273, 21875-21882.
203. Subbaramaiah, K.; Dannenberg, A. J. Resveratrol inhibits the expression of cyclooxygenase-2 in mammary epithelial cells. Adv. Exp. Med. Biol. 2001, 492, 147-157.
204. MacCarrone, M.; Lorenzon, T.; Guerrieri, P.; Agro, A. F. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur. J. Biochem. 1999, 265, 27-34.
205. Chung, E. Y.; Kim, B. H.; Lee, M. K.; Yun, Y. P.; Lee, S. H.; Min, K. R.; Kim, Y. Anti-inflammatory effect of the oligomeric stilbene alpha-Viniferin and its mode of the action through inhibition of cyclooxygenase-2 and inducible nitric oxide synthase. Planta Med. 2003, 69, 710-714.
206. Billard, C.; Izard, J. C.; Roman, V.; Kern, C.; Mathiot, C.; Mentz, F.; Kolb, J. P. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk. Lymphoma 2002, 43, 1991-2002.
207. Huang, K. S.; Lin, M.; Cheng, G. F. Anti-inflammatory tetramers of resveratrol from the roots of Vitis amurensis and the conformations of the seven-membered ring in some oligostilbenes. Phytochemistry 2001, 58, 357-362.
208. Zhong, M.; Cheng, G. F.; Wang, W. J.; Guo, Y.; Zhu, X. Y.; Zhang, J. T. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 1999, 6, 79-84.
209. Mahady, G. B.; Pendland, S. L. Resveratrol inhibits the growth of Helicobacter pylori invitro. Am. J. Gastroenterol. 2000, 95, 1849.
210. Wolter, F.; Akoglu, B.; Clausnitzer, A.; Stein, J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J. Nutr. 2001, 131, 2197-2203.
211. Tessitore, L.; Davit, A.; Sarotto, I.; Caderni, G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 2000, 21, 1619-1622.
212. Sengottuvelan, M.; Senthilkumar, R.; Nalini, N. Modulatory influence of dietary resveratrol during different phases of 1,2-dimethylhydrazine inducedmucosal lipidperoxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. Biochim. Biophys. Acta. 2006, 1760, 1175-1183.
213. Yan, S. L.; Huang, C. Y.; Wu, S. T.; Yin, M. C. Oleanolic acid and ursolic acid induce apoptosis in four human liver cancer cell lines. Toxicol. In vitro 2010, 24 (3), 842-848.
214. Wu, P. K.; Chi Shing, Tai, W.; Liang, Z. T.; Zhao, Z. Z.; Hsiao, W. L. Oleanolic acid isolated from Oldenlandia diffusa exhibits a unique growth inhibitory effect against ras-transformed fibroblasts. Life Sci. 2009, 85 (3-4), 113-121.
215. Furtado, R. A.; Rodrigues, E. P.; Araújo, F. R.; Oliveira, W. L.; Furtado, M. A.; Castro, M. B.; Cunha, W. R.; Tavares, D. C. Ursolic acid and oleanolic acid suppress preneoplastic lesions induced by 1,2-dimethylhydrazine in rat colon. Toxicol. Pathol. 2008, 36 (4), 576-580.
216. Siemoneit, U.; Pergola, C.; Jazzar, B.; Northoff, H.; Skarke, C.; Jauch, J.; Werz, O. On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies In vitro and pharmacological relevance. Eur. J. Pharmacol. 2009, 606 (1-3), 246-254.
217. Safayhi, H.; Sailer, E. R.; Ammon, H. P. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol. Pharmacol. 1995, 47 (6), 1212-1216.
218. Sailer, E. R.; Schweizer, S.; Boden, S. E.; Ammon, H. P.; Safayhi, H. Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur. J. Biochem. 1998, 256 (2), 364-368.
219. Glaser, T.; Winter, S.; Groscurth, P.; Safayhi, H.; Sailer, E. R.; Ammon, H. P.; Schabet, M.; Weller, M. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br. J. Cancer 1999, 80, 756-765.
220. Liu, J. J.; Duan, R. D. LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells. Anticancer Res. 2009, 29, 2987-2991.
221. Shao, Y.; Ho, C. T.; Chin, C. K.; Badmaev, V.; Ma, W.; Huang, M. T. Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Med. 1998, 64, 328-331.
222. Park, B.; Prasad, S.; Yadav, V.; Sung, B.; Aggarwal, B. B. Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets. PLoS One. 2011, 6 (10), e26943.
223. Liu, J. J.; Nilsson, A.; Oredsson, S.; Badmaev, V.; Zhao, W. Z.; Duan, R. D. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 2002, 23 (12), 2087-2093.
224. Yadav, V. R.; Prasad, S.; Sung, B.; Gelovani, J. G.; Guha, S.; Krishnan, S.; Aggarwal, B. B. Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int. J. Cancer. 2012, 130 (9), 2176-2184.
225. Huang, M. T.; Badmaev, V.; Ding, Y.; Liu, Y.; Xie, J. G.; Ho, C. T. Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-boswellic acid. Biofactors 2000, 13 (1-4), 225-230.
226. Safayhi, H.; Mack, T.; Sabieraj, J.; Anazodo, M.; Subramanian, L. R.; Ammon, H. P. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J. Pharmacol. Exp. Ther. 1992, 261 (3), 1143-1146.
227. Syrovets, T.; Buchele, B.; Krauss, C; Laumonnier, Y.; Simmet, T. Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-a induction in monocytes by direct interaction with IkB kinases. J. Immunol. 2005, 174 (1), 498-506.
228. Sudhakar, V.; Ashok Kumar, S.; Varalakshmi, P.; Sujatha, V. Protective effect of lupeol and lupeol linoleate in hypercholesterolemia associated renal damage. Mol. Cell Biochem. 2008, 317, 11-20.
229. Lima, L. M.; Perazzo, F. F.; Tavares Carvalho, J. C; Bastos, J. K. Anti-inflammatory and analgesic activities of the ethanolic extracts from Zanthoxylum riedelianum (Rutaceae) leaves and stem bark. J. Pharm. Pharmacol. 2007, 59, 1151-1158.
230. Fernández, M. A.; de las Heras, B.; García, M. D.; Sáenz, M. T.; Villar, A. New insights into the mechanism of action of the antiinflammatory triterpene lupeol. J. Pharm. Pharmacol. 2001, 53, 1533-1539.
231. Fernández, A.; Alvarez, A.; García, M. D.; Sáenz, M. T. Antiinflammatory effect of Pimenta racemosa var. ozua and isolation of the triterpene lupeol. Farmaco. 2001, 56, 335-338.
232. Davis, R. H.; DiDonato, J. J.; Johnson, R. W.; Stewart, C. B. Aloe vera, hydrocortisone and sterol influence on wound tensile strength and anti-inflammation. J. Am. Podiatr. Med. Assoc. 1994, 84 (12), 614-621.
233. Ramirez Apan, A. A.; Pérez-Castorena, A. L.; de Vivar, A. R. Antiinflammatory constituents of Mortonia greggii Gray. Z. Naturforsch C. 2004, 59, 237-243.
234. Gutierrez-Lugo, M. T.; Deschamps, J. D.; Holman, T. R.; Suarez, E.; Timmermann, B. N. Lipoxygenase inhibition by anadanthoflavone, a new flavonoid from the aerial parts of Anadenanthera colubrine. Planta Med. 2004, 70, 263-265.
235. Vasconcelos, J. F.; Teixeira, M. M.; Barbosa-Filho, J. M.; Lúcio, A. S.; Almeida, J. R.; de Queiroz, L. P. The triterpenoid lupeol attenuates allergic airway inflammation in a murine model. Int. Immunopharmacol. 2008, 8, 1216-1221.
236. Geetha, T.; Varalakshmi, P. Anticomplement activity of triterpenes from Crataeva nurvala stem bark in adjuvant arthritis in rats. Gen. Pharmacol. 1999, 32, 495-497.
237. Chaturvedula, V. S.; Schilling, J. K.; Miller, J. S.; Andriantsiferana, R.; Rasamison, V. E.; Kingston, D. G. New cytotoxic terpenoids from the wood of Vepris punctata from the Madagascar Rainforest. J. Nat. Prod. 2004, 67 (5), 895-898.
238. Lambertini, E.; Lampronti, I.; Penolazzi, L.; Khan, M. T. H.; Ather, A.; Giorgi, G.; Gambari, R.; Piva, R. Expression of estrogen receptor alpha gene in breast cancer cells treated with transcription factor decoy is modulated by bangladeshi natural plant extracts. Oncology Res. 2005, 14, 69-79.
239. Hata, K.; Hori, K.; Murata, J.; Takahashi, S. Remodeling of actin cytoskeleton in lupeol-induced B16 2F2 cell differentiation. J Biochem. 2005, 138 (4), 467-472.
240. Saleem, M.; Kaur, S.; Kweon, M. H.; Adhami, V. M.; Afaq, F.; Mukhtar, H. Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway. Carcinogenesis 2005, 26 (11), 1956-1964.
241. Gauthier, C; Legault, J.; Lebrun, M.; Dufour, P.; Pichette, A. Glycosidation of lupane-type triterpenoids as potent In vitro cytotoxic agents. Bioorg. Med. Chem. 2006, 14 (19), 6713-6725.
242. Lawrence, B. M. Major tropical spices cardamom (Elettaria cardamomum). In: Essential oils. Allured Publishers, Wheaton, 1979, p104.
243. Hashim, S.; Aboobaker, V. S.; Madhubala, R.; Bhattacharya, R. K.; Rao, A. R. Modulatory effects of essential oils from spices on the formation of DNA adduct by aflatoxin B1 In vitro. Nutr. Cancer 1994, 21 (2), 169-175.
244. Santos, F. A.; Rao, V. S. Antiinflammatory and antinociceptive effect of 1,8-Cineole a terpenoid oxide present in many plant essential oils. Phytother. Res. 2000, 14 (4), 240-244.
245. Juergens, U. R.; Stober, M.; Schmidt-Schilling, L.; Kleuver, T.; Vetter, H. Antiinflammtory effects of euclyptol (1,8-cineole) in bronchial asthma: Inhibition of arachidonic acid metabolism in human blood monocytes ex vivo. Eur. J. Med. Res. 1998, 3 (9), 407-412.
246. Juergens, U. R.; Engelen, T.; Racke, K.; Stober, M.; Gillissen, A.; Vetter, H. Inhibitory activity of 1,8-Cineole (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes. Pulm. Pharmacol. Ther. 2004, 17 (5), 281-287.
247. Sengupta, A.; Ghosh, S.; Bhattacharjee, S. Dietary cardamom inhibits the formation of azoxymethane induced aberrant crypt foci and reduces COX2 and iNOS expression in colon. Asian Pac. J. Cancer Prev. 2005, 6, 118-122.